ABIOMED News

Apple Inc. : Jim Cramer ranked this stock a Buy . The stock closed at $468.83, its 52-week high is $469.75, and its 52-week low is $310.50. Abiomed Inc.

Abiomed 's stock had its "outperform" rating reiterated by Zacks Investment Research in a report issued on Tuesday.

Research analysts at Wunderlich raised their price target on shares of Abiomed to $27.00 in a report issued on Monday.

Abiomed 's stock had its "buy" rating reiterated by analysts at Jefferies Group in a research report issued to clients and investors on Monday.

Jefferies reiterates its Buy rating on Abiomed and raises its price target by $1 to $25 a share as the company is poised to meet its seemingly lofty guidance following consecutive quarterly profitability.

Abiomed 's stock had its "buy" rating reaffirmed by research analysts at Wunderlich in a report issued on Wednesday.

Abiomed Inc. , a leading provider of breakthrough heart support technologies, today announced that the initial clinical data from the safety study for Symphonya was presented by Renzo Cecere, M.D., FRCSC, FACS, Associate Professor of Surgery at McGill University, during the late-breaking clinical trials session at the Society of Thoracic Surgeons ... (more)

HOTBEDS Regional News US & Canada Biotech Bay Biotech Beach Genetown Pharm Country BioCapital BioMidwest Bio NC BioForest Southern Pharm BioCanada East US Device Europe Asia New Clinical Data for Symphony Presented in Late Breaking Clinical Trials Session at the Society of Thoracic Surgeons 2012 Annual Meeting FORT LAUDERDALE, Fla.-- --Abiomed Inc.

Abiomed, Inc . announced today that on Friday, February 3, the Company will release financial results for the third quarter of fiscal 2012.